Introduction
Antithrombotic therapy, using various combinations of antiplatelet and anticoagulant drugs, is a cornerstone of the treatment of patients with coronary artery disease (CAD). 1 However, in several recent trials of new antithrombotic agents during or after acute coronary syndromes (ACS), ACS patients with a history of prior cerebrovascular disease (CVD) have derived no benefit (and in fact net clinical harm) from increasing the potency of antithrombotic therapy when the rest of the patients (i.e., pts with ACS but without prior history of CVD) derived benefit. [2] [3] [4] [5] In order to guide selection of treatments in this subset of patients, there is a need to further characterize the risk and type of ischemic (mortality, stroke, or MI) and bleeding events (particularly hemorrhagic stroke) associated with a history of prior CVD. Additionally, it is important to clarify the relationship between excess risk related to prior CVD with the type (stroke or transient ischemic attack, TIA) and timing (less or more than a year before enrollment) of prior CVD, and the impact of the type and intensity of antithrombotic therapy on such risk (single or dual antiplatelet therapy, anticoagulant therapy). The REACH (REduction of Atherothrombosis for Continued Health) registry is a large international registry of atherothrombotic patients with up to 4 years follow-up including patients with a history of coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD), or risk factors only. 6, 7 It therefore provides a unique opportunity to examine the rates and determinants of ischemic and bleeding outcomes in CAD patients with vs. without prior CVD.
Material and methods
The methods of the REACH Registry have been previously detailed. 8, 9 Briefly, the registry enrolled patients at least 45 years old with either 3 or more risk factors for atherosclerosis, or particularly hemorrhagic stroke) associated with a history of prior CVD. Additio io ona a al lly, y, y, i i it t t is is is mportant to clarify the relationship between excess risk related to prior CVD with the type s str tr rok ok oke e e or or t t tra ra r n n nsie e ent nt nt i ischemic attack, TIA) and tim m mi in ng (less or more re e tha an n n a a a year before enrollment) Endpoints were not adjudicated. Cardiovascular death included fatal stroke, fatal myocardial infarction, or other cardiovascular death (including death from pulmonary embolism; any sudden death unless proven otherwise by autopsy; death following a vascular operation, vascular procedure, or amputation; death attributed to heart failure; death following a visceral or limb infarction; and any other death that could not be definitely attributed to a nonvascular cause or haemorrhage). Any myocardial infarction or stroke followed by a death in the next 28 days, regardless of the cause, was considered to be a fatal myocardial infarction or fatal stroke. Strokes were categorized as ischemic, hemorrhagic or unknown on the basis of available imaging.
Cardiovascular hospitalization consisted of hospitalization for unstable angina, transient ischemic attack, worsening of claudication related to peripheral artery disease, other ischemic arterial event, coronary artery bypass grafting, coronary angioplasty/stenting, carotid surgery, carotid angioplasty/stenting, amputation affecting lower limbs, peripheral bypass graft, or angioplasty/stenting for peripheral artery disease. Different types of bleeding were recorded: non-fatal haemorrhagic strokes and bleeding requiring both hospitalization and transfusion.
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myocardial infarction, or other cardiovascular death (including death from pulmo ona ary ry e emb mbol oli ism; any sudden death unless proven otherwise by autopsy; death following a vascular operation, vasc cul ula ar p pro roc cedu ure re, or amputation; death attribu ute ted to heart failure e; deat ath h following a visceral or i imb b infarction; a an nd any ny oth ther er d dea ath th th hat t cou uld d not b be d de efin nit ite ely at ttrib bu ute ed to o a a nonv nvas a cu cula lar c cau use or h hae aemo m rr rha hage) ). A Any y m myo y ca ard rdia ial l in infa arc rcti tion on o or r st tro roke f fol ollo lowe wed d by by a a dea eath t i in n th the ne next 2 28 8 days ys, , egardless of f th the e ca caus use, e, w was as c con onsi side dere r d d to to b be e a a fa fata tal my myoc ocar ardi dial al i inf far arct ctio ion n or or f fat atal al s str trok o e. Stroke es The analysis was performed on the patients enrolled with CAD and included in the 4-year follow-up study. 7 Continuous variables are expressed as mean (standard deviation), and categorical variables are expressed as frequencies and percentages. Patients were divided into 2 groups according to history of CVD at enrolment in the registry. Comparison of baseline characteristics between the 2 groups was done using Student t test for continuous variables and Chi-Square test for categorical variables. Crude event rates were determined from 4-year Kaplan-Meier rates and were compared between the two groups using the log-rank test; for a given endpoint. We estimated the relative risk for a given endpoint associated with presence of CVD history through the calculation of hazard ratio using Cox proportional hazards model. The proportional hazards assumptions were checked using the log-log survival plots and by introducing time-dependent variables into Cox models. For non-bleeding outcomes, Cox proportional hazards models were further adjusted on the risk score predicting recurrent cardiovascular events derived from the REACH registry. 10 This score included age, sex, diabetes, smoking, body mass index <20 kg/m², history of atrial fibrillation, heart failure, history of cardiovascular events 1 year before baseline examination, number of vascular beds with clinical disease (CAD, CVD, PAD), use of statin and aspirin therapy at enrolment. For the purpose of the present analyses, the item of number of vascular beds was replaced by the item PAD (2 points was assigned for PAD history rather the 2, 4 and 6 points for one, two and three vascular beds, respectively). For bleeding outcomes, Cox proportional hazards models were adjusted for the bleeding risk score derived from the REACH registry. 11 This score includes the following variables: age, peripheral arterial disease, congestive heart failure, diabetes, hypertension, smoking, antiplatelets, oral anticoagulants and hypercholesterolaemia. Adjusted event rates are reported after adjustment on REACH risk scores quintile values using the corrected group proportional hazards assumptions were checked using the log-log survival plots s a a and 12 Because TIA is a subjective diagnosis, even among stroke subspecialists, we performed a sensitivity analysis considering separately stroke and prior TIA only as CVD history. 13 Subgroup analyses were done according to use of antiplatelet therapy and anticoagulant at baseline. Heterogeneity across subgroups was quantified by formal interaction tests. Statistical testing was done at the 2-tailed level of 0.05. Data were analysed using the SAS software package, release 9.3 (SAS Institute, Cary, NC).
Results

Baseline characteristics
Among the 45,227 patients enrolled in the REACH registry and followed for 4 years, 26,389 patients had established CAD at baseline. Among these, 4,460 (16.9%) had a concomitant history of CVD (2969 pts with prior stroke and 1491 pts with prior TIA only). The baseline characteristics of CAD patients with and without concomitant history of CVD are detailed in Table 1 . Patients enrolled with both CAD and CVD history were older, more frequently female, and were more likely to have a history of diabetes, hypertension, or atrial fibrillation than patients enrolled with only CAD. Regarding medication use at baseline, patients with history of both CAD and CVD more often received dual antiplatelet therapy and anticoagulant therapy than patients with CAD only. Overall, patients with both CAD and CVD history had a higher baseline risk of recurrent cardiovascular (CV) and bleeding events, as demonstrated by higher REACH risk scores.
Four-year CV event rates
As shown in Table 2 , patients with both CAD and CVD history had a higher rate of all-cause death (17.8% vs. 11 .2%) and CV events (24.9% vs. 13 .3% for CV death, MI or stroke) in Conversely, patients with prior TIA alone had a lower increase in stroke rate and no difference of death rate.
Impact of time from prior stoke/TIA on CV events
When considering time from prior stroke/TIA, the risk of all-cause death and MI was found to be similar for CAD patients with a prior stroke/TIA 1 year and >1 year before enrolment in the study. However, the time elapsed since the last CVD event had a major impact on the excess risk of stroke; a prior stroke/TIA 1 year before enrolment was associated with a greater risk of subsequent stroke than a more remote event: the adjusted event rate was 14.6% for prior stroke/
TIA 1 year vs. 9 .6% for prior stroke/ TIA > 1 year before enrolment; HR = 1.55 (1.28-1.87); p< 0.001 (Figure 3) .
Impact of antithrombotic therapy on CV events
The excess risk of CV events in patients with vs. without history of stroke/TIA was examined in absence of CVD history in CAD patients. The sensitivity analysis, excluding pati ien nts ts w wit ith h TI TIA A only, (Table 2 and Figure 2 ) showed similar observation in patient with prior stroke only.
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When conside deri ring ng t tim ime e from om p pri rior or st stro roke ke/T /TIA IA, , th the e ri risk s of of a all ll-c cau ause e d dea eath th a and nd M MI I wa was s found to b be patients receiving dual, single, and no antiplatelet therapy: the increased risk of CV death associated with prior CVD history was higher in CAD patients treated by dual antiplatelet therapy ( Supplemental Table 1 ) than for patients receiving single or no antiplatelet therapy:
adjusted HR for patients with prior CVD compared to those without = 1.51 (95% CI 1. 12 There was a significant interaction between risk of CV death and combined treatment with oral anticoagulant and antiplatelet agents (p for interaction = 0.049; see Supplemental   Table 2 ): the risk of CV death in patients with previous stroke/TIA was increased in patients treated with both anticoagulant and antiplatelet agents (adjusted HR = 1.33; 95%CI = 0.93-1.90) but not in those with anticoagulant and no antiplatelet agents (adjusted HR = 0.61; 95% CI = 0.34-1.08) or in those without anticoagulant and without antiplatelet agents (adjusted HR = 1.24;
95% CI = 1.09-1.42).
Four-year bleeding rates
Patients with both CAD and CVD history had higher bleeding rates than patients with only CAD 
Impact of time from prior stroke/TIA on non-fatal hemorrhagic stroke
The excess risk for non-fatal hemorrhagic stroke of patients with previous stroke/TIA compared with those without varied according to the time between CVD onset and enrollment (Figure 3) .
It appeared confined to the 1 st year following a stroke or TIA (adjusted HR, 3.03; 95%CI, 1.51 to 6 .08) whereas beyond 1 year, the risk was not increased (adjusted HR, 1.15; 95%CI, 0.53-2.47).
Similar observations were made after excluding patients with TIA (supplemental Figure) .
When comparing directly patients with previous stroke/TIA 1 year vs. those with previous stroke/TIA > 1 year the difference was significant: HR 2.64 (1.04-6.69), p = 0.041.
Impact of antithrombotic therapy on non-fatal hemorrhagic stroke
When the analysis was stratified according to antiplatelet therapy at admission, the increased risk of non-fatal hemorrhagic stroke was particularly high in patients receiving dual antiplatelet therapy (Figure 4) . In this subgroup, the adjusted HR of non-fatal hemorrhagic stroke associated with CVD history was 5 use of anticoagulant therapy with or without antiplatelet therapy (Supplemental Table 2 ; p for heterogeneity=0.69). However, for both of these analyses, the number of cerebral hemorrhagic events was low, and these rates should be interpreted conservatively.
Discussion
This analysis of the REACH registry revealed that in patients with CAD, a history of CVD is frequent (affecting approximately 17% of patients) and associated with an independent increase in risk of death, MI, or stroke. This greater risk of stroke (13.1 vs. 4 .1%) was observed both for nonfatal ischemic (9.6% vs. 2 .5%) and nonfatal hemorrhagic stroke (0.6% vs. 0.3%). While the former was much higher in absolute terms, the latter is a concern when considering increased potency of antithrombotic interventions. This excess risk of hemorrhagic stroke was particularly high in patients receiving dual antiplatelet therapy and in the first year following stroke/TIA.
An increased risk of ischemic events has already been reported in patients with a history of stroke/TIA [14] [15] [16] . This increased risk has been confirmed in patient presenting with ACS or with stable atherosclerosis and having a history of stroke/TIA. [17] [18] [19] In patients with CAD, an increased risk of hemorrhagic stroke in pts with a history of CVD has been observed across several randomized trials evaluating novel antithrombotic agents.
The TRACER trial, evaluating the addition of vorapaxar, a PAR-1 antagonist, to standard therapy in patients with ACS found an increased risk of major bleeding, including intracranial haemorrhage. 3 A subgroup analysis showed a trend toward an increased risk of bleeding in patients with previous stroke. The TRA-2P trial evaluated vorapaxar in a secondary prevention setting. 4 In this trial, vorapaxar reduced the primary ischemic composite endpoint compared with placebo but with a significant increase in bleeding, including intracranial haemorrhage both in former was much higher in absolute terms, the latter is a concern when consideri rin ng ng i in nc cre re reas as ased ed ed potency of antithrombotic interventions. This excess risk of hemorrhagic stroke was particularly hi igh gh gh i i in n n pa pa ati ti tien en nts r r rec ec ecei e ving dual antiplatelet therapy py py a a and in the first t ye y ar ar f f fo ol ollowing stroke/TIA.
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In the TRITON-TIMI 38 trial, comparing prasugrel to clopidogrel in ACS patients treated with PCI, prasugrel reduced rates of ischemic events at a price of an increased risk of major bleeding in the overall population. 2 A post hoc analysis identified patients with previous stroke or TIA as deriving net clinical harm from prasugrel (HR 1.54; 95% CI, 1.02 to 2.32; p = 0.04) contrasting with the overall results (HR 0.81; 95% CI, 0.73 to 0.90; P<0.001). This was mainly due an excess bleeding risk including intracranial hemorrhage in this subgroup. Moreover, there was a significant interaction between a history of cerebrovascular events and the net clinical benefit of prasugrel over clopidogrel.
The PLATO trial demonstrated a benefit of ticagrelor vs. clopidogrel in ACS patients in reducing the risk of primary composite ischemic outcome (cardiovascular death, myocardial infarction or stroke). 20 In the subgroup of patients with previous stroke/TIA, this trial contrasts with the previous since the rates of bleeding, according to the PLATO definition, were similar with ticagrelor and clopidogrel. However, when looking at the overall trial population, there was a trend toward more intracranial bleeding in the ticagrelor group (0.3% vs. 0.2%; p=0.06).
The APPRAISE-2 trial evaluating apixaban, a factor Xa inhibitor, in addition to standard therapy after recent ACS, was terminated prematurely because of an increase in major bleeding events with apixaban without a significant reduction in recurrent ischemic events. 21 In patients or TIA as deriving net clinical harm from prasugrel (HR 1.54; 95% CI, 1.02 to 2. with previous stroke, apixaban was associated with worse outcome regarding the primary efficacy endpoint (p for interaction 0.08).
Rivaroxaban, another factor Xa inhibitor, was evaluated on top of dual antiplatelet therapy in the ATLAS ACS 2 trial. In that trial, rivaroxaban reduced the risk of the primary composite endpoint but increased the risk of major bleeding and intracranial hemorrhage in the overall trial population. 5 There were too few bleeding events in the subgroup of patients with prior stroke / TIA (4 events in the rivaroxaban arm, 0 in the placebo arm) to allow comparison.
Therefore, in patients with CAD, recent trials evaluating novel anticoagulant or antiplatelet therapies in addition to standard antithrombotic therapy suggest an increased risk of hemorrhagic stroke in patients with previous stroke. Our results confirm and extend these observations but should not be construed as suggesting no benefit for antithrombotic therapy in the secondary prevention of stroke / TIA. The latter is well established and the absolute risk of hemorrhagic stroke (0.6%) remains largely inferior to the absolute risk of ischemic stroke (11.7%). 22 Whether the high ischemic risk in this subgroup can be overcome by increasing the potency of antithrombotic therapy remains however to be demonstrated. The increased risk of bleeding resulting in such a strategy should be carefully taken into consideration.
Atherothrombotic patients who experience serious bleeding have been shown to have a more than three-fold increase risk of ischemic events. 23 Moreover, as we observed in the present analysis, increasing antithrombotic therapy might not be safe considering the disproportionate increase in hemorrhagic stroke, particularly in patients receiving dual antiplatelet therapy.
Similarly, in the MATCH trial that compared, in patients with recent stroke or TIA, a single antiplatelet therapy (clopidogrel) to a dual antiplatelet therapy (clopidogrel + aspirin), the dual hemorrhagic stroke in patients with previous stroke. Our results confirm and ext te e end d d th h hes e ese e e observations but should not be construed as suggesting no benefit for antithrombotic therapy in h he e se se seco co cond nd ndar ar a y y y pr rev ev even e tion of stroke / TIA. The la a att tt tter r r is well establi li ish s ed ed d a a an nd n the absolute risk of h he hem mo morrhagic st stro ro ok ke e ( ( (0. 0 0 6% 6% %) ) ) re re rem ma main in ns s la lar rg rge ely in in i f ferio or or to th th the e ab a abs so solu lu ute e r ris isk k k o of f i is sc sch he hemi mi mic st st s ro ro oke ke ke r 1 11. 1. 1.7% 7% 7%). ). ). 22 2 Whet the he her r r th th he e e hi hi igh gh h isc sc sche he h mi mi mic c c ri ri risk sk i i in n n th th this is is s s sub ub ubgr gr grou ou o p p ca ca can n n be be be o o ove ve v rc rc rcom om ome e e by by by inc nc ncre re reas as asin in ing the by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from antiplatelet therapy did not significantly reduce ischemic events but was associated with an increase in life-threatening or major bleeding. 24 Therefore, CAD patients with previous CVD represent a therapeutic conundrum: given the high risk of CV event, physicians may be tempted to use dual or triple preventive antithrombotic therapies, yet the disproportionate increase of hemorrhagic stroke often will prevent use of these agents. Further clinical characterization is needed since not all CAD patients with prior CVD seem to have the same balance of risk: we observed in the sensitivity analysis that patients with prior stroke had an increase in nonfatal ischemic stroke and nonfatal hemorrhagic stroke associated with an increased risk of death; whereas CAD patients with prior TIA only had a lower increase in stroke rate and no increase in non-fatal hemorrhagic stroke associated with no increase in death rate compared to patients with no previous TIA (Figure 2) .
Similarly, the time elapsed since the last CVD event also appears to have a major impact on the excess risk of stroke; a prior stroke/TIA 1 year before enrolment was associated with a greater risk of subsequent stroke than a more remote event. The explanation for this observation remains unclear since hematoencephalic barrier healing usually occurs within a few weeks after a stroke, not within one year. One explanation could be a decrease in the intensity of antithrombotic therapy after one year. This hypothesis would be consistent with the increase in hemorrhagic stroke we observed in patients with previous stroke under dual antiplatelet therapy.
Further studies are required in this large group of patients at high risk to define the best antithrombotic strategy and to optimize ischemic and hemorrhagic balance. Until novel safer antithrombotic strategies are developed and evaluated, prevention of recurrent ischemic events in this population subset may require more aggressive management of atherothombosis risk factors rather than increased potency of antithrombotic therapies.
TIA only had a lower increase in stroke rate and no increase in non-fatal hemorrh rh hag g gic ic s s str tr trok ok oke e e associated with no increase in death rate compared to patients with no previous TIA (Figure 2) .
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Conclusion
In patients with CAD, a history of stroke/TIA is associated with an independent increase in risk of death, MI, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute terms). This excess risk of hemorrhagic stroke is particularly high in patients receiving dual antiplatelet therapy and in the first year following stroke/TIA. This observation is important for selection of antithrombotic therapy in these patients. * log-rank test. † sensitivity analysis was conducted after exclusion of CAD patients enrolled with only history of TIA. ‡ sensitivity analysis was conducted after exclusion of CAD patients enrolled with history of stroke. § HRs were adjusted on components of the REACH prediction model of secondary cardiovascular events for non-bleeding outcomes and on REACH bleeding risk score for bleeding outcomes.
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All-cause death 11 2969 CAD patients were enrolled in REACH with concomitant history of stroke (905 with stroke within 1 year of enrollment).
CAD indicates coronary artery disease; CVD, cerebrovascular disease; CV, cardiovascular disease;
MI, myocardial infarction. HR, hazard ratio; CI, confidence interval. Event rates and HRs were adjusted on REACH risk scores.
